Dosimetry of a novel amino acid PET tracer, [18F]FELP
Phase 1
- Conditions
- GlioblastomaTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-501696-91-00
- Lead Sponsor
- niversitair Ziekenhuis Gent
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets does [18F]FELP PET tracer bind to in glioblastoma tumor metabolism?
How does [18F]FELP compare to [18F]FDG and [11C]MET in glioblastoma tumor imaging accuracy?
Which amino acid transporters or metabolic biomarkers correlate with [18F]FELP uptake in GBM patients?
What adverse events are associated with [18F]FELP administration in phase I oncology trials?
Are there synergistic imaging strategies combining [18F]FELP with other glioblastoma-targeted PET tracers?